Tezepelumab Reduces Mucus Plugs in Adults With Uncontrolled Asthma
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, Sept. 29, 2023 -- Tezepelumab is associated with a reduction in occlusive mucus plugs versus placebo in adults with uncontrolled asthma, according to a study published in the October issue of NEJM Evidence.
Lars H. Nordenmark, Ph.D., from AstraZeneca in Oslo, Norway, and colleagues assessed the anti-inflammatory effect of tezepelumab in participants of the CASCADE trial, in which patients (aged 18 to 75 years old) with moderate-to-severe, uncontrolled asthma were randomly assigned (1:1) to 210 mg tezepelumab (37 patients) or placebo (45 patients) every four weeks subcutaneously for at least 28 weeks.
The researchers found that the absolute change from baseline in mean mucus plug score was −1.7 in patients receiving tezepelumab and 0.0 in patients receiving placebo. There was a positive correlation observed at baseline between mucus plug scores and levels of inflammatory biomarkers (blood eosinophils, eosinophil-derived neurotoxin, fractional exhaled nitric oxide, interleukin-5, and interleukin-13), as well as a negative association with lung function measures (prebronchodilator forced expiratory volume in 1 second and forced mid-expiratory flow). Reductions in mucus plug scores for patients receiving tezepelumab were correlated with improvements in lung function and reductions in blood eosinophil count and levels of eosinophil-derived neurotoxin, a biomarker of eosinophilic degranulation.
"The reduction in occlusive mucus plugs in these patients is consistent with the idea that reducing mucus plugs is a component of the salutary therapeutic effect of tezepelumab," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and Amgen, which manufacture tezepelumab and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Clinical Response Seen for Patients With Severe Asthma Initiating Biologics
FRIDAY, June 28, 2024 -- Patients with severe asthma initiating biologics exhibit clinical responses and super-responses, but 40 to 50 percent do not meet response criteria...
Aerobic Exercise Tied to Improved Clinical Asthma Outcomes
MONDAY, June 24, 2024 -- Moderate- and vigorous-intensity aerobic exercise training are associated with improvements in clinical asthma outcomes, according to a study published...
Few Adults With Moderate, Severe Asthma Receive Recommended Inhaler Regimen
THURSDAY, May 23, 2024 -- Only 14.5 percent of adult patients with moderate or severe asthma are prescribed the recommended Single Maintenance and Reliever Therapy (SMART) inhaler...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.